大博集团品牌怎么样 申请店铺

我要投票 大博集团在男科医院行业中的票数:95 更新时间:2025-02-23
大博集团是哪个国家的品牌?「大博集团」是 大博医疗科技股份有限公司 旗下著名品牌。该品牌发源于福建省厦门市,由创始人林 * 雄在2004年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力大博集团品牌出海!通过在本页面挂载大博集团品牌的产品链接和联系邮箱,可以提高大博集团产品曝光!跨境电商爆单神器,目前只要100元/年哦~

大博集团怎么样

成立于2004年,以骨科、神经外科、微创外科为主的综合性医疗集团,与世界各地的专家建立良好的合作关系和经验交流


大博简介

大博医疗科技股份有限公司,成立于2004年,坐落于美丽的鹭岛——厦门,是一家以骨科、神经外科、微创外科为主的综合性医疗集团。公司先后通过了FDA、CE、ISO13485、GMP等专业认证,产品品质不断超越国际标准,得到国内外用户的一致认可。

研发制造

紧密结合临床,是大博开展研发工作的基石。经多年的钻研沉淀,与国内北上广等地的知名专家,以及澳大利亚、瑞士等国际专家,皆建立起良好的合作关系,广纳临床专家的实践经验,坚持不懈地进行产品和技术的提升与创新。同时,大博成立了厦门骨科医疗器械工程技术研究中心、与厦门大学联合成立厦大化工——大博医疗外科材料研发中心、同时还与台湾科技大学合办产学研项目,并承接多个科技项目。引进国际加工设备,以高度机械化的生产工艺,依托科学的质量管理体系,精心打造各种医疗产品,涵盖骨科、齿科、微创外科、神经外科、医用电子、医疗设备等。

营销网络

大博在产品、推广、服务等各方面进行创新,在全国多省均设有物流平台,构建便捷的物流网络。与近千家经销商通力合作,不断提高服务效率,及时地为3500余家医院提供优质的服务。同时,大博设立专业的“咨询服务与技术支持”团队,为客户提供医疗器械使用方法及技术要点咨询服务,解决医师在临床上遇到的困难和问题。“高品质,赢天下”。大博放眼全球,实行国际化战略布局,拥有涵盖英语、俄语、拉丁语等多语种的国际营销部门,产品直接出口至澳大利亚、瑞士、俄罗斯、乌克兰等20多个国家和地区。

发展战略

为配合企业前进的步伐,大博制定了四化发展战略:专业化——专攻医疗产品,只做业内前三;多元化——在医疗领域内实现产品多元化,打造综合性医用高值材料供应商;国际化——国际化发展战略,产品研发销售皆面向国际市场;创新化——产品研发、企业发展立足创新,推出创新性医疗产品,坚持以创新驱动发展企业。进行以产品为核心的研发、制造、教育、推广。


Founded in 2004, a comprehensive medical group focusing on orthopedics, neurosurgery and minimally invasive surgery, established a good cooperation relationship and experience exchange with experts from all over the world. Dabo Medical Technology Co., Ltd., founded in 2004, is located in Xiamen, the beautiful island of heron. It is a comprehensive medical group focusing on orthopedics, neurosurgery and minimally invasive surgery. The company has passed FDA, CE, ISO13485, GMP and other professional certification. The product quality continues to exceed international standards, and has been unanimously recognized by users at home and abroad. R & D and manufacturing are closely combined with clinical practice, which is the cornerstone of Dabo's R & D work. After years of research and precipitation, we have established good cooperation with well-known experts in China, Beijing, Shanghai, Guangzhou and other places, as well as international experts in Australia, Switzerland and other places. We have widely accepted the practical experience of clinical experts, and have been unremitting in product and technology upgrading and innovation. At the same time, Dabo has established Xiamen orthopedic medical device engineering technology research center, Xiamen University and Xiamen University to jointly establish Xiamen University chemical - Dabo medical surgical material research and development center. At the same time, Dabo and Taiwan University of science and technology jointly run production, teaching and research projects, and undertake a number of scientific and technological projects. With the introduction of international processing equipment, highly mechanized production process, and relying on scientific quality management system, we have carefully built various medical products, including orthopedics, dentistry, minimally invasive surgery, neurosurgery, medical electronics, medical equipment, etc. The marketing network is innovative in products, promotion, services and other aspects. It has logistics platforms in many provinces across the country to build a convenient logistics network. Cooperate with nearly 1000 distributors to improve service efficiency and provide quality services to more than 3500 hospitals in a timely manner. At the same time, Dabo has set up a professional "consulting service and technical support" team to provide customers with consulting services on the use methods and technical points of medical devices, so as to solve the clinical difficulties and problems encountered by doctors. "High quality, win the world". Dabo has a global perspective and an international strategic layout. It has an international marketing department covering English, Russian, Latin and other languages. Its products are directly exported to more than 20 countries and regions, including Australia, Switzerland, Russia, Ukraine and so on. Development strategy in line with the pace of enterprise progress, Dabo has formulated four development strategies: Specialization - specializing in medical products, only making the top three in the industry; diversification - realizing product diversification in the medical field, creating comprehensive medical high-value material suppliers; internationalization - international development strategy, product R & D and sales are oriented to the international market; innovation - Product R & D Based on innovation, the development of enterprises will launch innovative medical products and adhere to innovation driven development of enterprises. Carry out R & D, manufacturing, education and promotion with products as the core.

本文链接: https://brand.waitui.com/2fe6bfaf5.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

天岳先进:2024年净利润1.8亿元 同比扭亏为盈

36氪获悉,天岳先进发布业绩快报,公司2024年实现营业收入17.68亿元,同比增长41.37%;实现归属于母公司所有者的净利润1.80亿元,同比扭亏为盈。主要原因是公司大尺寸、导电型产品产能产量持续提升,销售量增加,同时产品毛利率上升。

2分钟前

小米集团卢伟冰:小米15 Ultra会是越级式的一代产品

36氪获悉,小米集团合伙人兼总裁、手机部总裁、小米品牌总经理卢伟冰发文称,小米手机未来5年高端化的目标之一,就是要在6000元+价格段实现规模化的突破,“Ultra是6K+突破的关键产品,而小米15 Ultra会是越级式的一代产品”。

2分钟前

恒瑞医药:羟乙磺酸达尔西利片联合内分泌治疗乳腺癌III期临床试验达主要终点

36氪获悉,恒瑞医药公告称,公司自主研发的羟乙磺酸达尔西利片在激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性女性乳腺癌辅助治疗的III期临床试验中,首次期中分析主要终点达到统计学显著性。研究结果显示,达尔西利联合内分泌治疗可显著降低患者复发风险,提高患者无侵袭性疾病生存期(IDFS)。公司已向国家药品监督管理局药品审评中心递交上市前沟通交流申请。该药品是公司自主研发的化学药品1类新药,是一种口服、高效、选择性的小分子CDK4/6抑制剂。

2分钟前

深圳:近期将发布人形机器人专项政策 在全市科技重大专项中安排人工智能和机器人专项

深圳市政府新闻办2月23日召开“打造最好科技创新生态和人才发展环境”主题新闻发布会。市人工智能产业办主任林毅在会上表示,深圳在人工智能和机器人领域基础雄厚、未来可期。下一步,我们将在政策、场景、创新、机器人四个方面持续发力。此外,近期我们还将发布人形机器人专项政策,通过“揭榜挂帅”等方式,对开放应用场景、突破关键技术、构建专用数据集、提升规模化制造和应用能力等予以精准支持。同时,还将在全市科技重大专项中安排人工智能和机器人专项,鼓励产、学、研、用组成创新联合体进行协同攻关。(财联社)

2分钟前

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

2分钟前

本页详细列出关于郑州颐和医院的品牌信息,含品牌所属公司介绍,郑州颐和医院所处行业的品牌地位及优势。
咨询